Biophage reaches an important milestone in the development & comercialization of its PDS(R) Biosensor
Reception of the alpha prototype and initiation of the final testing and validation stage before launching the product
Biophage Pharma Inc announced that it has reached an important milestone in the development and commercialization of its PDS(R) Biosensor. Reception of the first manufacturing prototype allows the company to enter Phase 4 of its development program consisting of extensive product tests in both the market place and in different labs (beta sites) before launch.
A typical 'Stage-Gate(R) product development process' consists of four stages. Phase 1 is the initial R&D leading to a laboratory prototype, while Phase 2 and 3 consist of building a business case and the detailed design and development of the new product. Reception of the first manufacturing prototype (alpha prototype) is an important milestone in this approach mainly because it allows the product to enter in its final design and validation phase (Phase 4) before its commercialization.
"We are extremely pleased by the speed and high quality performance of our production partner in the design and development of this alpha prototype of our PDS(R) Biosensor," commented Dr. Mandeville, President and CEO of Biophage Pharma. "Reaching this important milestone puts us a step closer to a full-scale professional product sample that will be presented to our potential buyers and to corporations for licensing. We have already chosen four different Beta testing sites for the completion of Phase 4 of our development and commercialization process." added Dr Mandeville.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
